Alirocumab, sold under the brand name Praluent, is a medication used as a second-line treatment for high cholesterol for adults whose cholesterol is not...

Regeneron's drug alirocumab infringed Amgen's patents; Amgen then requested an injunction barring Regeneron and Sanofi from marketing alirocumab, which was...

can lower LDL particle concentrations. The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the...

metastatic colorectal cancer approved by the FDA in August 2012. Praluent (alirocumab) is indicated as an adjunct to diet and maximally tolerated statin therapy...

Injectable antibodies against the protein PCSK9 (evolocumab, bococizumab, alirocumab) can reduce LDL cholesterol and have been shown to reduce mortality. In...

2024 MA 2001 Valdecoxib 2016 N/A SM 2001 Etoricoxib 2016 N/A SM 2003 Alirocumab 2015 2035 MA 2006 Linagliptin 2011 2031 SM 2007 Apixaban 2012 2032 SM...

(Clopidogrel), for atherothrombosis, marketed by Bristol-Myers Squibb. Praluent (Alirocumab), for heterozygous familial hypercholesterolemia and clinical atherosclerotic...

Alemtuzumab Lemtrada, Campath mab humanized CD52 Y multiple sclerosis Alirocumab Praluent mab human PCSK9 Y hypercholesterolemia Altumomab pentetate Hybri-ceaker...

importance of early identification of FH and treatment with statins. Alirocumab and evolocumab, both monoclonal antibodies against PCSK9, are specifically...

intravenous humanized CD52 B-cell chronic lymphocytic leukemia 103948 Link alirocumab Praluent Sanofi Aventis 7/24/2015 subcutaneous fully human PCSK9 Heterozygous...